BI-97C1 is a potent small-molecule inhibitor that targets the Bcl-2 family of proteins, which play a key role in regulating apoptosis (programmed cell death). Its primary application lies in cancer research, particularly in the development of therapies for tumors that overexpress anti-apoptotic proteins like Bcl-2, Bcl-xL, and Mcl-1. By inhibiting these proteins, BI-97C1 promotes mitochondrial outer membrane permeabilization, leading to caspase activation and cancer cell death. It has shown promising activity in preclinical studies against several hematological malignancies and solid tumors, including leukemia, lymphoma, and lung cancer. Due to its ability to overcome resistance mechanisms associated with conventional chemotherapy, BI-97C1 is being explored as a potential agent in combination therapies. Researchers are also investigating its use in sensitizing cancer cells to other treatments such as radiation or targeted drugs, enhancing overall therapeutic efficacy.